Skip to main content

Minimal Change Disease clinical trials at UCSF

2 in progress, 1 open to eligible people

Minimal change disease leads to protein leakage from the kidneys. UCSF is conducting trials with various drugs like Frexalimab to assess their safety and effectiveness. The study involves participants between 16 and 75 years old.

Showing trials for

Our lead scientists for Minimal Change Disease research studies include .

Last updated: